Trial Profile
Phase II Study for Inoperable Non-Metastatic Pancreatic Cancer (Stage IVA) With Neoadjuvant Gemzar, Taxotere and Xeloda (GTX), and Radiation With Gemzar
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 19 Apr 2016 Status changed from active, no longer recruiting to completed.
- 05 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jul 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2014 as reported by ClinicalTrials.gov.